BioLineRx Ltd. (BLRX) Form 6-K — May 22, 2026
BioLineRx and partner Hemispherian AS are presenting two abstracts on GLIX1 at the ASCO 2026 Annual Meeting, highlighting preclinical data for this first-in-class oral TET2 activator in glioblastoma and other cancers. The data demonstrates that GLIX1 effectively restores TET2 activity, leading to tumor-selective DNA damage, with strong antitumor activity in glioblastoma xenograft models and efficient brain penetration (68-85% of plasma levels). A second abstract outlines synergistic antitumor activity when combining GLIX1 with PARP inhibitors across multiple cancer types, providing a mechanistic rationale for future combination trials.
Key figures
- Abstract numbers
- ["e14072","e13129"]
- Max dose dogs mg kg
- 1000
- Max dose rats mg kg
- 2000
- Trial patients part1
- 30
- Brain exposure percent
- 68-85% of plasma levels
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.